Clinical Trial Detail

NCT ID NCT01453205
Title A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

diffuse large B-cell lymphoma

Therapies

Cisplatin + Cytarabine + Dexamethasone

Carboplatin + Etoposide + Ifosfamide

Rituximab

MEDI-551

Age Groups: adult

No variant requirements are available.